Our findings revealed that SERCA2 and SERCA2-mediated Ca2+ dynamics could serve as key therapeutic targets for improving bone mechano-responsiveness in patients with T2D. This evidence concerns the gene ATP2A2 and type 2 diabetes mellitus.